Revisión de las terapias biológicas en la enfermedad inmunomediada del oído interno

McCabe, 1979, Autoimmune sensorineural hearing loss, Ann Otol Rhinol Laryngol, 88, 585, 10.1177/000348947908800501 García-Berrocal, 2004, Glucocorticoids: the best therapy for immune-mediated inner ear disease, Curr Topics Steroid Res, 4, 99 Lobo, 2008, Diagnostic tests for immunomediated hearing loss: a systematic review, J Laryngol Otol, 122, 564, 10.1017/S002221510700059X García-Berrocal, 2007, Autoimmune hearing loss: improving diagnostic performance, Acta Otorrinolaringol Esp, 58, 138, 10.1016/S2173-5735(07)70321-6 García-Berrocal, 2008, Adverse effects of glucocorticoid therapy for inner ear disorders, ORL J Otorhinolaryngol Relat Spec, 70, 271, 10.1159/000134381 Harris, 2003, Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial, JAMA, 290, 1875, 10.1001/jama.290.14.1875 García-Berrocal, 2006, Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: a physiopathologic approach, Eur Arch Otorhinolaryngol, 263, 977, 10.1007/s00405-006-0096-9 Herráiz, 2010, Intratympanic drug delivery for the treatment of inner ear diseases, Acta Otorrinolaringol Esp, 61, 225, 10.1016/S2173-5735(10)70039-9 Moreland, 1999, Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial, Ann Intern Med, 130, 478, 10.7326/0003-4819-130-6-199903160-00004 Satoh, 2002, Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation, Laryngoscope, 112, 1627, 10.1097/00005537-200209000-00019 Hawkins, 2004, Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra, Arthritis Rheum, 50, 607, 10.1002/art.20033 Rahman, 2001, Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study, Otol Neurotol, 22, 619, 10.1097/00129492-200109000-00010 Matteson, 2005, Etanercept therapy for immune-mediated cochleovestibular disorders: a multicenter, open-label, pilot study, Arthritis Rheum, 53, 337, 10.1002/art.21179 Cohen, 2005, Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study, Otol Neurotol, 26, 903, 10.1097/01.mao.0000185082.28598.87 Liu, 2011, Treatment-refractory autoimmune sensorineural hearing loss: response to infliximab, Ear Nose Throat J, 90, 23, 10.1177/014556131109000107 Van Wijk, 2006, Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss, Audiol Neurootol, 11, 357, 10.1159/000095897 Street, 2006, Etanercept, a tumor necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss, J Laryngol Otol, 120, 1064, 10.1017/S0022215106002593 Morovic Vergles, 2010, Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: two birds with one stone, J Rheumatol, 37, 1080, 10.3899/jrheum.091342 Staecker, 2002, Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report, Acta Otolaryngol, 112, 1627 Rigante, 2006, Hydrocephalus in CINCA syndrome treated with anakinra, Childs Nerv Syst, 22, 334, 10.1007/s00381-006-1280-3 Rynne, 2006, Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism, Ann Rheum Dis, 65, 533, 10.1136/ard.2005.038091 Gerard, 2007, Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra, Joint Bone Spine, 74, 659, 10.1016/j.jbspin.2007.01.032 Cohen, 2011, A pilot study of rituximab in immune-mediated inner ear disease, Audiol Neurootol, 16, 214, 10.1159/000320606 Orsoni, 2010, Rituximab ameliorated severe hearing loss in Cogan's syndrome: a case report, Orphanet J Rare Dis, 5, 18, 10.1186/1750-1172-5-18 Lasak, 2001, Autoimmune inner ear disease: steroid and cytotoxic drug therapy, Ear Nose Throat J, 80, 808, 10.1177/014556130108001110 Broughton, 2004, Immune-mediated inner ear disease: 10-year experience, Semin Artritis Rheum, 34, 544, 10.1016/j.semarthrit.2004.07.001 Moreland, 2001, Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis, J Rheumatol, 28, 1238 Keystone, 2007, Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis, Arthritis Rheum, 56, 3896, 10.1002/art.23059 Carswell, 1975, An endotoxin-induced serum factor that causes necrosis of tumors, Proc Natl Acad Sci U S A, 72, 3666, 10.1073/pnas.72.9.3666 Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. J Assoc Res Otolaryngol. 2003;4:139–47. Hess, 1999, Expression of inducible nitric oxide synthase (iNOS/NOS II) in the cochlea of guinea pigs after intratympanical endotoxin-treatment, Brain Res, 830, 113, 10.1016/S0006-8993(99)01433-X Wang, 2003, Blockage of immune-mediated inner ear damage by etanercept, Otol Neurotol, 24, 52, 10.1097/00129492-200301000-00012 Lobo, 2006, TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoinmune experimental labyrinthitis, Eur Arch Otorhinolaryngol, 263, 622, 10.1007/s00405-006-0027-9 Aganna, 2002, Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis, Arthritis Rheum, 46, 2445, 10.1002/art.10509